Merck & Co., Inc. (ETR:6MK)
71.40
-0.30 (-0.42%)
Aug 15, 2025, 5:35 PM CET
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B USD in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.32
Revenue / Employee
$848.21K
Employees
75,000
Market Cap
179.63B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Merck & Co. News
- 3 days ago - 10 Undervalued Dividend Growth Stocks: August 2025 - Seeking Alpha
- 3 days ago - Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer - Seeking Alpha
- 3 days ago - KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Wallstreet:Online
- 3 days ago - KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Business Wire
- 4 days ago - IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study - Seeking Alpha
- 8 days ago - August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys - Seeking Alpha
- 9 days ago - Stock Picks From Seeking Alpha's July 2025 New Analysts - Seeking Alpha
- 10 days ago - Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Wallstreet:Online